1. 614TiPUCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis. (23rd October 2018) Authors: Mazard, T; Ghiringhelli, F; Mollevi, C; Assenat, E; Gavoille, C; Smith, D; Pezzella, V; Meddeb, R; Pastor, B; Ychou, M; Thierry, A R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P11.19.B Bevacizumab in recurrent WHO grade 2-3 gliomas. (5th September 2022) Authors: Annakib, S; Rigau, V; Darlix, A; Gozé, C; Duffau, H; Bauchet, L; Mollevi, C; Fabbro, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗